Charles River Laboratories (CRL) : Healthinvest Partners Ab reduced its stake in Charles River Laboratories by 16.09% during the most recent quarter end. The investment management company now holds a total of 149,612 shares of Charles River Laboratories which is valued at $13,019,236 after selling 28,695 shares in Charles River Laboratories , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Charles River Laboratories makes up approximately 5.71% of Healthinvest Partners Ab’s portfolio.
Other Hedge Funds, Including , Boston Advisors added CRL to its portfolio by purchasing 4,070 company shares during the most recent quarter which is valued at $354,171. Charles River Laboratories makes up approx 0.01% of Boston Advisors’s portfolio.Gemmer Asset Management reduced its stake in CRL by selling 62 shares or 28.44% in the most recent quarter. The Hedge Fund company now holds 156 shares of CRL which is valued at $13,538. Charles River Laboratories makes up approx 0.01% of Gemmer Asset Management’s portfolio.Ls Investment Advisors boosted its stake in CRL in the latest quarter, The investment management firm added 1,279 additional shares and now holds a total of 3,137 shares of Charles River Laboratories which is valued at $272,229. Charles River Laboratories makes up approx 0.02% of Ls Investment Advisors’s portfolio.Checchi Capital Advisers boosted its stake in CRL in the latest quarter, The investment management firm added 27 additional shares and now holds a total of 190 shares of Charles River Laboratories which is valued at $16,488.Van Berkom Associates reduced its stake in CRL by selling 21,585 shares or 3.16% in the most recent quarter. The Hedge Fund company now holds 662,313 shares of CRL which is valued at $57,475,522. Charles River Laboratories makes up approx 2.51% of Van Berkom Associates’s portfolio.
Charles River Laboratories opened for trading at $87.55 and hit $88.5599 on the upside on Friday, eventually ending the session at $87.93, with a gain of 0.49% or 0.43 points. The heightened volatility saw the trading volume jump to 2,62,588 shares. Company has a market cap of $4,148 M.
On the company’s financial health, Charles River Laboratories reported $0.98 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.90. The company had revenue of $354.90 million for the quarter, compared to analysts expectations of $354.81 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.
Many Wall Street Analysts have commented on Charles River Laboratories. Credit Suisse Initiated Charles River Laboratories on Jun 21, 2016 to “Neutral”, Price Target of the shares are set at $84.Company shares were Reiterated by Barclays on May 20, 2016 to “Underweight”, Firm has raised the Price Target to $ 65 from a previous price target of $60 .
Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.